At the beginning of the Year of the Horse, on the afternoon of February 26th, the "New Overseas Chinese Innovation and Entrepreneurship in Shanghai" activity, organized by the Shanghai Federation of Returned Overseas Chinese to visit overseas Chinese enterprises and facilitate practical work, entered Zhangjiang Pharma Valley and held a thematic seminar at Lishan Biotech. A delegation comprising Qi Quansheng, Party Secretary and Chairman of the Shanghai Federation of Returned Overseas Chinese; Guo Qing, Vice Chairman of the Municipal Federation and concurrently Party Secretary and Chairman of the Pudong New Area Federation; and Cheng Dong, Chairman of the Zhangjiang Science City Federation, among others, visited the company. Li Zhi, Deputy Director of Corporate Communications at Junshi Biosciences, and Shang Jing, Executive Director of the Shanghai Standards Innovation Center, were invited to attend the seminar. They engaged in in-depth discussions with the Lishan Bio team on topics including industry development trends, technological innovation pathways, industrial development prospects, and resource integration for overseas Chinese enterprises, pooling the wisdom of the overseas Chinese community to stimulate innovation synergy.

Before the seminar, the municipal federation delegation conducted an on-site visit to Lishan Bio's R&D laboratory. Dr. Yu Fei, Director of the Drug Research Center at Lishan Biotech, provided a detailed introduction to the laboratory's facility configuration and the latest R&D progress.

During the seminar session, Dr. Chen Weijie, Chairman of Lishan Biotech; Dr. Zhu Chaoyu, Director of the Bioinformatics Center; and Guo Yushan, Director of the Scientific Research Project Management Center, respectively shared systematic insights into the company's three-year development journey, the clinical progress of its Crohn's disease and renal cell carcinoma pipelines, the AI empowerment practices of the IMicAP platform, and future commercialization plans. Attendees, considering the current development challenges faced by Lishan Bio, conducted in-depth discussions on topics such as the domestic and international industrial landscape, collaborative innovation mechanisms, and resource connection pathways.

Li Zhi, Deputy Director of Corporate Communications at Junshi Biosciences, shared the pioneering experiences accumulated over Junshi's 15-year history from the perspective of an established, scaled pharmaceutical company. She stated that Junshi Biosciences' growth trajectory, from initially focusing on breakthroughs in core pipelines for survival to now building a pipeline echelon and expanding its domestic and international market layout, illustrates the essential stages a biopharmaceutical enterprise must pass through to progress from "survival" to "strength."

Shang Jing, Executive Director of the Shanghai Standards Innovation Center, explained that the center's core function is to transform cutting-edge technological advantages into industry standards. Through preliminary research, experimental validation, and standard drafting, it aims to facilitate the conversion of technological achievements into practical productivity. The center is dedicated to providing full-chain standardization support for biopharmaceutical companies, assisting them in establishing standard systems, particularly during the product commercialization stage at key technological junctures, and thereby contributing to the elevation of the industry's overall standard.

In his concluding remarks, Qi Quansheng pointed out that the municipal federation's New Year visits to overseas Chinese enterprises chose Zhangjiang Pharma Valley as its first stop to inspect a startup overseas Chinese enterprise, meet with the "post-90s" returned overseas Chinese scientific innovation team, build communication platforms, and promote cooperation among overseas Chinese enterprises. Three years ago, when the company was first established, the municipal federation visited for an inspection. This visit, witnessing the company's rapid development and significant changes, was very encouraging. He noted that relying on the Zhangjiang Pharma Valley incubation platform, gathering young scientific talent from home and abroad, maintaining close cooperation with domestic and international research institutions, focusing on cutting-edge leading technologies and products with industrialization potential, emphasizing the integration of AI technology with biomedicine, actively conducting financing, and upholding the spirit of hard work, unity, and tenacity are all valuable experiences in Lishan Bio's development. He stated that today's communication was deep and fruitful. The municipal, district, and park overseas Chinese federations will continue to leverage their role as bridges and bonds, precisely align with the development needs of overseas Chinese enterprises, build platforms for communication and resource integration among relevant parties, provide tangible assistance for the innovative development of these enterprises, and help them make greater contributions in pioneering industries and other sectors.

Chen Weijie expressed that this visit and inspection by the municipal federation is both an affirmation and support for Lishan Biotech's innovative development, injecting new momentum into the company's subsequent growth. In the future, Lishan Biotech will live up to expectations, continue to seize opportunities in the biopharmaceutical industry, deepen its research and development of intestinal microecological live biotherapeutic products, and continuously enhance its core competitiveness. The company will actively integrate into the overseas Chinese innovation ecosystem, strengthen industry exchanges and cooperation, and contribute to the development of new quality productive forces in the national and Shanghai biopharmaceutical industries with its innovative achievements and products, demonstrating the responsibility and commitment of an overseas Chinese enterprise.